Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling
Company to host scientific workshop featuring emerging eMTBR-Tau and BD-pTau217 research data for Alzheimer’s disease detection and staging Fremont, CA, July 10, 2026 (GLOBE NEWSWIRE) — Alamar…
Read the full articleYou might also wanna read
https://doi.org/10.1126/science.aeb6987
Blood biomarker pinpoints when Alzheimer's shift from amyloid to tau occurs—with precision, improving early intervention prospects. PMID:420
The BRidge Towards Implementation of Blood-based Biomarkers to Enable Early and Accurate Diagnosis of Alzheimer's Disease
Conditions : Alzheimer Blood Biomarkers; Alzheimer's Disease (AD) Interventions : Diagnostic Test: Plasma p-tau217 and neurofilament light c
Evaluation System for Lecanemab Efficacy Using Gold Electrode ECL to Monitor Alzheimer's Biomarkers
Conditions : Alzheimer Disease Interventions : Drug: Lecanemab Sponsors : The Fourth Affiliated Hospital of Zhejiang University School of Me
Roche Aktie: Neue Alzheimer-Daten im Juli
Roche geht einen ungewöhnlichen Weg in der Alzheimer-Forschung. Der Schweizer Pharmakonzern verknüpft seine Diagnostik-Sparte mit der Entwic
ALZEVIT: Nationwide Digital APOE ε4 Cohort for Early Alzheimer's Disease Prevention and Trial Readiness
Conditions : Alzheimer Sponsors : Firalis SA; CHU de Reims; University Hospital, Marseille; Centre Hospitalier Universitaire de Nice; Univer
Nura raises $73.8M to target ALS through a unique target
Biospace reports that Nura Bio has raised $73.8 million in financing to carry two neuroprotective drug candidates through early to mid-stage
Comments
Sign in to join the conversation.
No comments yet. Be the first.